Abstract

Background: Hypertension and dyslipidemia are two cardiovascular risk factors that often combine in clinical practice and increase acute coronary syndrome and cerebrovascular disease complications. Statins are the most widely used drugs to treat dislipidemia in clinical practice. Among them, pitavastatin has an LDL-c lowering effect similar or even superior to that of other statins, but a significantly higher ability to increase HDL-c levels. Objectives: (i) To determine the rate of dislipidemia in primary hypertensive patients; (ii) To identify some ralated factors to dislipidemia in primary hypertensive patients; (iii) To evaluate the effect on controlling LDL-c, HDL-c and side effects of pitavastatin in patients at moderate/ low risk of cardiovascular diseases. Subjects and methods: Descriptive cross-sectional study, conducted on 116 primary hypertensive patients with dyslipidemia at the Department of Examination – Can Tho University of Medicine and Pharmacy Hospital. Results: The prevalence of dislipidemia among primary hypertensive patients was 88%. There was a relationship between dislipidemia with: duration of hypertension, BMI, waist circumference, physical inactivity, alcohol abuse and fatty liver status. The proportion of patients with LDL-C reaching the treatment target was 84%. The increasing concentration of HDL-c was 9.65%. Side effects: the rate of ALT increases above 3 times normal was 2% (1 patient). Conclusion: Dyslipidemia accounts for a very high proportion among patients with hypertension, especially in patients with other associated cardiovascular risk factors such as overweight, obesity, alcohol abuse and physical inactivity. Pitavastatin is good at controlling LDL-c, HDL-c and highly safe.